RE:RE:RE:BLA status VS approvalLike I said, my valuation was very conservative, 500 patients or ~1%-2% of the MDR market. If this is peak sales it would be very disappointing. I work in big pharma doing market share statistical models for a living, we should have much higher penetration. Patient access is one of the biggest hurdles (outside of FDA approval) that we will have to deal with and unfortunately I do not know much about the USA reimbursement climate outside of what has been shared here. I was hoping we had someone with USA patient access experience however from what I hear is the listings could be slow and it could be around Q2 before we have the majority of insurers who will cover this very life critical therapy in place.